-
EP3923987
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3923987
| EP3923987 - USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 17.11.2023 Database last updated on 03.06.2024 | |
| Former | Request for examination was made Status updated on 19.11.2021 | ||
| Former | The international publication has been made Status updated on 22.08.2020 | ||
| Former | unknown Status updated on 19.02.2020 | Most recent event Tooltip | 17.04.2024 | New entry: Application deemed to be withdrawn: despatch of communication + time limit | Applicant(s) | For all designated states Institut National de la Santé et de la Recherche Médicale (INSERM) 101 rue de Tolbiac 75013 Paris / FR | For all designated states Université Paul Sabatier Toulouse III 118, route de Narbonne 31400 Toulouse / FR | For all designated states CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) 3, rue Michel-Ange 75016 Paris / FR | [2021/51] | Inventor(s) | 01 /
MANENTI, Stéphane Centre de Recherche en Cancérologie de Toulouse CRCT), INSERM U1037/CNRS ERL 5294, 2 avenue Hubert Curien 31037 TOULOUSE CEDEX 1 / FR | 02 /
DIDIER, Christine Centre de Recherche en Cancérologie de Toulouse CRCT), INSERM U1037/CNRS ERL 5294, 2 avenue Hubert Curien 31037 TOULOUSE CEDEX 1 / FR | 03 /
CARTEL, Maëlle Centre de Recherche en Cancérologie de Toulouse CRCT), INSERM U1037/CNRS ERL 5294, 2 avenue Hubert Curien 31037 TOULOUSE CEDEX 1 / FR | [N/P] |
| Former [2021/51] | 01 /
MANENTI, Stéphane 31037 TOULOUSE CEDEX 1 / FR | ||
| 02 /
DIDIER, Christine 31037 TOULOUSE CEDEX 1 / FR | |||
| 03 /
CARTEL, Maëlle 31037 TOULOUSE CEDEX 1 / FR | Representative(s) | Inserm Transfert PariSanté Campus 10 rue d'Oradour-sur-Glane 75015 Paris / FR | [N/P] |
| Former [2021/51] | Inserm Transfert 7, rue Watt 75013 Paris / FR | Application number, filing date | 20704030.4 | 13.02.2020 | [2021/51] | WO2020EP53711 | Priority number, date | EP20190305181 | 14.02.2019 Original published format: EP 19305181 | [2021/51] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2020165315 | Date: | 20.08.2020 | Language: | EN | [2020/34] | Type: | A1 Application with search report | No.: | EP3923987 | Date: | 22.12.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 20.08.2020 takes the place of the publication of the European patent application. | [2021/51] | Search report(s) | International search report - published on: | EP | 20.08.2020 | Classification | IPC: | A61K45/00, A61P35/02 | [2021/51] | CPC: |
A61K45/00 (EP);
A61K31/381 (US);
A61K31/7068 (US);
A61P35/02 (US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/51] | Title | German: | VERWENDUNG VON USP7-INHIBITOREN ZUR BEHANDLUNG VON AKUTER MYELOIDER LEUKÄMIE (AML) | [2021/51] | English: | USE OF USP7 INHIBITORS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML) | [2021/51] | French: | UTILISATION D'INHIBITEURS DE L'USP7 POUR LE TRAITEMENT DE LA LEUCÉMIE AIGUË MYÉLOÏDE (LAM) | [2021/51] | Entry into regional phase | 05.08.2021 | National basic fee paid | 05.08.2021 | Designation fee(s) paid | 05.08.2021 | Examination fee paid | Examination procedure | 05.08.2021 | Amendment by applicant (claims and/or description) | 05.08.2021 | Examination requested [2021/51] | 05.08.2021 | Date on which the examining division has become responsible | 21.11.2023 | Despatch of a communication from the examining division (Time limit: M04) | 16.04.2024 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | Fees paid | Renewal fee | 17.02.2022 | Renewal fee patent year 03 | 22.02.2023 | Renewal fee patent year 04 | Penalty fee | Additional fee for renewal fee | 29.02.2024 | 05 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]WO2016126929 (FORMA THERAPEUTICS INC [US]) [A] 1-10 * paragraphs [0021] , [0 24] *; | [A] - PERL, "The role of targeted therapy in the management of patients with AML.", HEMATOLOGY. AMERICAN SOCIETY OF HEMATOLOGY. EDUCATION PROGRAM, (20170208), vol. 2017, no. 1, XP002793133 [A] 1-10 * pages 54, 57,; table 1 * | [A] - CHEN CHAO ET AL, "Synthesis and biological evaluation of thiazole derivatives as novel USP7 inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, (20170110), vol. 27, no. 4, doi:10.1016/J.BMCL.2017.01.018, ISSN 0960-894X, pages 845 - 849, XP029906433 [A] 1-10 * table 1 * DOI: http://dx.doi.org/10.1016/j.bmcl.2017.01.018 | by applicant | US5981732 | US6046321 | US6107091 | US6365354 | US6410323 | US6566135 | US6566131 | WO2010081783 | WO2013030218 | WO2016109480 | US9840491 | US9902728 | US9932351 | US9938300 | US10000495 | - VARDIMAN J WHARRIS N LBRUNNING R D, "The World Health Organization (WHO) classification of the myeloid neoplasms", Blood, (20020000), vol. 100, no. 7, doi:10.1182/blood-2002-04-1199, pages 2292 - 302, XP055458874 DOI: http://dx.doi.org/10.1182/blood-2002-04-1199 | - BENNETT JCATOVSKY DDANIEL MFLANDRIN GGALTON DGRALNICK HSULTAN C, "Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group", Br J Haematol, (19760000), vol. 33, no. 4, pages 451 - 8 | - "Principles of Cancer Therapy", SLAPAKKUFE, Harrison's Principles of Internal medicine | - WANDER S.A., TherAdv Hematol., (20140000), vol. 5, pages 65 - 77 | - TAP et al., N Engl J Med, (20150000), vol. 373, pages 428 - 437 | - SMITH et al., Blood, (20150000), vol. 126, no. 23 | - LI et al., Mol. Cancer Ther., (20150000), vol. 14, pages 375 - 83 | - LOBRY COH PMANSOUR MRLOOK ATAIFANTIS I, "Notch signaling: switching an oncogene to a tumor suppressor", Blood, (20140000), vol. 123, no. 16, pages 2451 - 2219 | - EVERETT R. D.MEREDITH M.ORR A.CROSS AKATHORIA M.PARKINSON J., "A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpes virus regulatory protein", EMBO J., (19970000), vol. 16, no. 7, pages 1519 - 30 | - HOLOWATY M. N.ZEGHOUFM.WU H. et al., "Protein profiling with Epstein-Barr nuclear antigen-1 reveals an interaction with the herpesvirusassociated ubiquitin-specific protease HAUSP/USP7", J. Biol. Chem., (20030000), vol. 278, no. 32, doi:10.1074/jbc.M303977200, pages 29987 - 94, XP002266783 DOI: http://dx.doi.org/10.1074/jbc.M303977200 | - DESROSES MALTUN M, "The Next Step Forward in Ubiquitin-Specific Protease 7 Selective Inhibition", Cell Chem Biol., (20171221), vol. 24, no. 12, doi:10.1016/j.chembiol.2017.12.003, pages 1429 - 1431, XP085326770 DOI: http://dx.doi.org/10.1016/j.chembiol.2017.12.003 | - GAVORY GO'DOWD CRHELM MDFLASZ JARKOUDIS EDOSSANG AHUGHES CCASSIDY EMCCLELLAND KODRZYWOL E, "Discovery and characterization of highly potent and selective allosteric USP7 inhibitors", Nat Chem Biol., (20180200), vol. 14, no. 2, doi:10.1038/nchembio.2528, pages 118 - 125, XP055453500 DOI: http://dx.doi.org/10.1038/nchembio.2528 | - JINGBLIUMYANG LCAI HYCHEN JBLI ZXKOU XWU YZQINDJZHOU L, "Characterization of naturally occurring pentacyclic triterpenes as novel inhibitors of deubiquitinating protease USP7 with anticancer activity in vitro", Acta Pharmacol Sin., (20180300), vol. 39, no. 3, pages 492 - 498 | - DI LELLO PPASTOR RMURRAY JMBLAKE RACOHEN FCRAWFORD TDDROBNICK JDRUMMOND JKATEGAYA LKLEINHEINZ T, "Discovery of Small-Molecule Inhibitors of Ubiquitin Specific Protease 7 (USP7) Using Integrated NMR and in Silico Techniques", J Med Chem., (20171228), vol. 60, no. 24, pages 10056 - 10070 | - ZHOU JWANG JCHEN CYUAN HWEN XSUN H, "USP7: Target Validation and Drug Discovery for Cancer Therapy", Med Chem., (20180000), vol. 14, no. 1, pages 3 - 18 | - LAMBERTO ILIU XSEO HSSCHAUER NJIACOB REHU WDAS DMIKHAILOVA TWEISBERG ELENGEN JR, "Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7", Cell Chem Biol., (20171221), vol. 24, no. 12, pages 1490 - 1500,e11 | - POZHIDAEVA AVALLES GWANG FWU JSTERNER DENGUYEN PWEINSTOCK JKUMAR KGSKANYO JWRIGHT D, "USP7-Specific Inhibitors Target and Modify the Enzyme's Active Site via Distinct Chemical Mechanisms", Cell Chem Biol., (20171221), vol. 24, no. 12, pages 1501 - 1512 | - TURNBULL APIOANNIDIS SKRAJEWSKI WWPINTO-FERNANDEZ AHERIDE CMARTIN ACLTONKIN LMTOWNSEND ECBUKER SMLANCIA DR, "Molecular basis of USP7 inhibition by selective small-molecule inhibitors", Nature, (20171026), vol. 550, no. 7677, doi:10.1038/nature24451, pages 481 - 486, XP055453666 DOI: http://dx.doi.org/10.1038/nature24451 | - KATEGAYA LDI LELLO PROUGE LPASTOR RCLARK KRDRUMMOND JKLEINHEINZ TLINEUPTON JPPRAKASH S, "USP7 small-molecule inhibitors interfere with ubiquitin binding", Nature, (20171026), vol. 550, no. 7677, pages 534 - 538 | - ALTUN MKRAMER HBWILLEMS LIMCDERMOTT JLLEACH CAGOLDENBERG SJ et al., "Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes", Chem Biol, (20110000), vol. 18, doi:10.1016/j.chembiol.2011.08.018, pages 1401 - 1412, XP055217598 DOI: http://dx.doi.org/10.1016/j.chembiol.2011.08.018 | - DOHNER HWEISDORF DJBLOOMFIELD CD, "Acute myeloid leukemia", N Engl J Med., (20150000), vol. 373, pages 1136 - 1152 | - PAPAEMMANUIL EGERSTUNG MBULLINGER L et al., "Genomic Classification and Prognosis in Acute Myeloid Leukemia", N Engl J Med., (20160000), vol. 374, no. 23, pages 2209 - 2221 | - YANG MZHAO JLIU T et al., "Use of FLT3 inhibitors in acute myeloid leukemia remission induction or salvage therapy: systematic review and meta-analysis", Cancer Manag Res., (20180000), vol. 10, pages 2635 - 2652 | - DINARDO CDSTEIN EMDE BOTTON S et al., "Durable Remissions with Ivosidenib in IDHI-Mutated Relapsed or Refractory AML", N Engl J Med., (20180000), vol. 378, no. 25, pages 2386 - 2398 | - ZHOU JCHNG WJ, "Resistance to FLT3 inhibitors in acute myeloid leukemia: Molecular mechanisms and resensitizing strategies", World J Clin Oncol., (20180000), vol. 9, no. 5, pages 90 - 97 | - DAVID LFERNANDEZ-VIDAL ABERTOLI S et al., "CHK1 as a therapeutic target to bypass chemoresistance in AML", Sci Signal., (20160000), vol. 9, no. 445 | - ZHANG YWOTTERNESS DMCHIANG GG et al., "Genotoxic stress targets human Chk1 for degradation by the ubiquitin-proteasome pathway", Mol Cell, (20050000), vol. 19, pages 607 - 618 | - HUH JPIWNICA-WORMS H, "CRL4CDT2 targets CHK1 for PCNA-independdent destruction", Mol Cell Biol., (20130000), vol. 33, pages 213 - 226 | - LEUNG-PINEDA VHUH JPIWNICA-WORMS H, "DDB1 targets Chk1 to the Cul4 E3 ligase complex in normal cycling cells and ini cells experiencing replication stress", Cancer res., (20090000), vol. 69, pages 2630 - 2637 | - ZHANG YWBROGNARD JCOUGHLIN C et al., "The F Box Protein Fbx6 regulates Chk1 srability and cellular sensitivity to replication stress", Mol Cell, (20090000), vol. 35, pages 442 - 453 | - GUERVILLY JHRENAUD ETAKATA MROSSELLI F, "USP1 deubiquitinase maintains phosphorylated CHK1 by limiting its DDB1 -dependent degradation", Hum Mol Genet., (20110000), vol. 20, no. 11, pages 2171 - 81 | - CHENG YCSHIEH SY, "Deubiquitinating enzyme USP3 controls CHK1 chromatin association and activation", PNAS, (20180000), vol. 115, no. 21, pages 5546 - 51 | - ALONSA DE VEGA IMARTIN YSMITS VAJ, "USP7 controls Chk1 protein stability by direct deubiquitination", Cel Cycle, (20140000), vol. 13, pages 3921 - 3926 | - TAVANA OGU W, "Modulation of the p53/MDM2 interplay by HAUSP inhibitors", Journal of Mol Cell Bio, (20170000), vol. 9, no. 1, pages 45 - 52 | - LI MBROOKS CLKON NGU W, "A dynamic role of HAUSP in the p53-Mdm2 pathway", Mol Cell, (20040000), vol. 13, no. 6, pages 879 - 886 | - BROOKS CLGU W, "p53 ubiquitination : Mdm2 and beyond", Mol Cell, (20060000), vol. 21, no. 3, pages 307 - 315 | - MUNGAMURI SKQIAO RFYAO SMANFREDI JJGU WAARONSON SA, "USP7 Enforces Heterochromatinization of p53 Target Promoters by Protecting SUV39H1 from MDM2-Mediated Degradation", Cell Rep., (20160000), vol. 14, no. 11, pages 2528 - 37 | - BASU BSAHA GCHOUDHURY SGGHOSH MK, "Cellular homeostasis or tumorigenesis : USP7 playing the double agent", Cancer Cell and MicroEnv., (20170000), page 4 | - VAN DER KNAAP JAKUMAR BRMOSHKIN YM, "GMP synthetase stimulates histone H2B deubiquitylation by the epigenetic silencer USP7", Mol Cell, (20050000), vol. 17, no. 5, pages 695 - 707 | - FAUSTRUP HBEKKER-JENSEN SBARTEK JLUKAS JMAILAND N, "USP7 counteracts SCFbetaTrCP- but not APCCdhl-mediated proteolysis of Claspin", J Cell Biol., (20090000), vol. 184, no. 1, pages 13 - 9 | - DU ZSONG JWANG Y et al., "DNMT1 stability is regulated by proteins coordinating deubiquitination and acetylation-driven ubiquitination", Sci Signal, (20100000), vol. 3, no. 146, page ra80 | - ZHU QSHARMA NHE JWANI GWANI AA, "USP7 deubiquitinase promotes ubiquitin-dependent DNA damage signaling by stabilizing RNF168", Cell Cycle, (20150000), vol. 14, no. 9, pages 1413 - 25 | - VAN DER HORST ADE VRIES-SMITS AMBRENKMAN AB et al., "FOX04 transcriptional activity is regulated by monoubiquitination and USP7/HAUSP", Nat Cell Biol., (20060000), vol. 8, no. 10, pages 1064 - 73 | - SONG MSSALMENA LCARRACEDO A et al., "The deubiquitinylation and localization of PTEN are regulated by a HAUSP-PML network", Nature, (20080000), vol. 455, no. 7214, pages 813 - 7 | - VAN DER KNAAP JAKOZHEVNIKOVA ELANGENBERG KMOSHKIN YMVERRIJZER CP, "Biosynthetic enzyme GMP synthetase cooperates with ubiquitin-specific protease 7 in transcriptional regulation of ecdysteroid target genes", Mol Cell Biol., (20100000), vol. 30, no. 3, pages 736 - 44 | - HOLOWATY MNFRAPPIER L, "HAUSP/USP7 as an Epstein-Barr virus target", Biochem Soc Trans., (20040000), vol. 32, no. 5, pages 731 - 2 | - DU ZSONG JWANG Y et al., "DNMT1 stability is regulated by proteins coordinating deubiquitination and acetylation-driven ubiquitination", Sci Signal., (20100000), vol. 3, no. 146, page ra80 | - EVERETT RD.MEREDITH M.ORR A.CROSS A.KATHORIA M.PARKINSON J., "A novel ubiquitin-specific protease is dynamically associated with the PML nuclear domain and binds to a herpesvirus regulatory protein", EMBO J., (19970000), vol. 16, pages 1519 - 1530 | - NICHOLSON BMARBLESTONE JGBUTT TRMATTERN MR, "Deubiquitinating enzymes as novel anticancer targets", Future Oncol., (20070000), vol. 3, no. 2, pages 191 - 9 | - D'ARCY PWANG XLINDER S, "Deubiquitinase inhibition as a cancer therapeutic strategy", Pharmacol Ther., (20150000), vol. 147, doi:10.1016/j.pharmthera.2014.11.002, pages 32 - 54, XP029196209 DOI: http://dx.doi.org/10.1016/j.pharmthera.2014.11.002 | - KATEGAYA LDI LELLO PROUGE L et al., "USP7 small-molecule inhibitors interfere with ubiquitin binding", Nature, (20170000), vol. 550, no. 7677, pages 534 - 538 | - TURNBULL APIOANNIDIS SKRAJEWSKI WW et al., "Molecular basis of USP7 inhibition by selective small-molecule inhibitors", Nature, (20170000), vol. 550, no. 7677, doi:10.1038/nature24451, pages 481 - 486, XP055453666 DOI: http://dx.doi.org/10.1038/nature24451 | - LAMBERTO ILIU XSEO HS et al., "Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7", Cell Chem Biol., (20170000), vol. 24, no. 12, pages 1490 - 1500 | - POZHIDAEVA AVALLES GWANG F et al., "USP7-Specific Inhibitors Target and Modify the Enzyme's Active Site via Distinct Chemical Mechanisms", Cell Chem Biol., (20170000), vol. 24, no. 12, pages 1501 - 1512 | - GAVORY GO'DOWD CRHELM MD et al., "Discovery and characterization of highly potent and selective allosteric USP7 inhibitors", Nat Chem Biol., (20180000), vol. 14, no. 2, doi:10.1038/nchembio.2528, pages 118 - 125, XP055453500 DOI: http://dx.doi.org/10.1038/nchembio.2528 | - CARRA GPANUZZO CTORTI D et al., "Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones", Oncotarget, (20170000), vol. 8, no. 22, pages 35508 - 35522 | - CHAUHAN DTIAN ZNICHOLSON B et al., "A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance", Cancer Cell, (20120000), vol. 22, no. 3, doi:10.1016/j.ccr.2012.08.007, pages 345 - 58, XP002747465 DOI: http://dx.doi.org/10.1016/j.ccr.2012.08.007 | - FAN YHCHENG JVASUDEVAN SA et al., "USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis", Cell Death Dis., (20130000), vol. 4, doi:10.1038/cddis.2013.400, page e867, XP055451124 DOI: http://dx.doi.org/10.1038/cddis.2013.400 | - NETWORK TCGAR, "Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia", N Engl J Med., (20130000), vol. 368, doi:10.1056/NEJMoa1301689, pages 2059 - 74, XP055101067 DOI: http://dx.doi.org/10.1056/NEJMoa1301689 | - VERHAAK RGWWOUTERS BJERPELINCK CAJ et al., "Prediction of molecular subtypes in acute myeloid leukemia based on gene expression profiling", Haematologica, (20090000), vol. 94, pages 131 - 4 | - FARGE TSALAND EDE TONI F et al., "Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism", Cancer Discov., (20170000), vol. 7, no. 7, doi:10.1158/2159-8290.CD-16-0441, pages 716 - 735, XP009513011 DOI: http://dx.doi.org/10.1158/2159-8290.CD-16-0441 | - EPPERT KTAKENAKA KLECHMAN ER et al., "Stem cell gene expression programs influence clinical outcome in human leukemia", Nat Med., (20110000), vol. 17, doi:10.1038/nm.2415, pages 1086 - 93, XP055611746 DOI: http://dx.doi.org/10.1038/nm.2415 | - AN TGONG YLI X et al., "USP7 inhibitor P5091 inhibits Wnt signaling and colorectal tumor growth", Biochem Pharmacol., (20170000), vol. 131, doi:10.1016/j.bcp.2017.02.011, pages 29 - 39, XP029949833 DOI: http://dx.doi.org/10.1016/j.bcp.2017.02.011 | - ZHAO GYLIN ZWLU C et al., "USP7 overexpression predicts a poor prognosis in lung squamous cell carcinoma and large cell carcinoma", Tumour Biol., (20150000), vol. 36, no. 3, doi:10.1007/s13277-014-2773-4, pages 1721 - 9, XP036218115 DOI: http://dx.doi.org/10.1007/s13277-014-2773-4 | - MA MYU N, "Ubiquitin-specific protease 7 expression is a prognostic factor in epithelial ovarian cancer and correlates with lymph node metastasis", Onco Targets Ther., (20160000), vol. 9, pages 1559 - 69 | - SHAN HLI XXIAO X et al., "USP7 deubiquitinates and stabilizes NOTCH1 in T-cell acute lymphoblastic leukemia", Signal Transduct Target Ther, (20180000), vol. 3, page 29 | - WANG SITOH MSHIRATORI EOHTAKA MTOHDA S, "NOTCH activation promotes glycosyltransferase expression in human myeloid leukemia cells", Hematol Rep., (20180000), vol. 10, no. 3, page 7576 | - XU XZHAO YXU M et al., "Activation of Notch signal pathway is associated with a poorer prognosis in acute myeloid leukemia", Med Oncol., (20110000), vol. 28, no. 1, doi:10.1007/s12032-010-9667-0, pages 483 - 9, XP019991085 DOI: http://dx.doi.org/10.1007/s12032-010-9667-0 |